GS-0976 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
PD Effects of GS-0976 (NDI-010976) on Fractional DNL
Conditions
PD Effects of GS-0976 (NDI-010976) on Fractional DNL
Trial Timeline
Aug 1, 2015 → Oct 1, 2015
NCT ID
NCT02876796About GS-0976 + Placebo
GS-0976 + Placebo is a phase 1 stage product being developed by Gilead Sciences for PD Effects of GS-0976 (NDI-010976) on Fractional DNL. The current trial status is completed. This product is registered under clinical trial identifier NCT02876796. Target conditions include PD Effects of GS-0976 (NDI-010976) on Fractional DNL.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02876796 | Phase 1 | Completed |
Competing Products
10 competing products in PD Effects of GS-0976 (NDI-010976) on Fractional DNL
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment C | Daiichi Sankyo | Phase 1 | 33 |
| Budesonide Nasal | Johnson & Johnson | Approved | 85 |
| SHR-1603 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Albuterol Sulfate + Nicardipine Hydrochloride + Dobutamine Hydrochloride + Phenylephrine Hydrochloride + Verapamil Hydrochloride + Phentolamine Mesylate + Placebo | AstraZeneca | Phase 1 | 33 |
| daptomycin | Merck | Phase 3 | 77 |
| Cyclosporine & Cellcept + Prograf & Cellcept + Low Dose CNI (Cyclosporine or FK) and Cellcept + Rapamune and Cellcept | Roche | Phase 1/2 | 41 |
| Evolocumab | Amgen | Phase 1 | 32 |
| Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine | Sanofi | Phase 1 | 32 |
| BG9418 (interferon beta-1a) | Biogen | Pre-clinical | 20 |
| Placebo spray and oral moxifloxacin placebo + Sativex spray and oral moxifloxacin placebo + Sativex spray and oral moxifloxacin placebo + Placebo spray and moxifloxacin | Jazz Pharmaceuticals | Phase 1 | 30 |